The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
These findings follow positive Phase 3 results presented earlier this year
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
